Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000848 · ClinicalTrials.gov registry record · Phase 2
The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 16
- Study locations
NCT00000848: Completed Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000848 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 144 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (68% lower). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000848, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 16
- Study locations
Study Summary
To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA. Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have shown that cross-resistance occurs among protease inhibitors, although no clinical trials have been conducted to examine antiretroviral activity with sequential use of protease inhibitors or to determine whether saquinavir resistance can be overcome with higher concentrations of the drug.
Conditions Studied
Interventions
- DRUG Indinavir sulfate
- DRUG Saquinavir
Study Locations (16)
New York
- SUNY - Buffalo, Erie County Medical Ctr. - Buffalo
- Beth Israel Med. Ctr. (Mt. Sinai) - New York
- NY Univ. HIV/AIDS CRS - New York
- Univ. of Rochester ACTG CRS - Rochester
California
- Stanford CRS - Palo Alto
- Ucsf Aids Crs - San Francisco
- Harbor-UCLA Med. Ctr. CRS - Torrance
Illinois
- Northwestern University CRS - Chicago
- Rush Univ. Med. Ctr. ACTG CRS - Chicago
Missouri
- Washington U CRS - St Louis
- St. Louis ConnectCare, Infectious Diseases Clinic - St Louis
Colorado
- University of Colorado Hospital CRS - Aurora
Florida
- Univ. of Miami AIDS CRS - Miami
Massachusetts
- Massachusetts General Hospital ACTG CRS - Boston
Ohio
- The Ohio State Univ. AIDS CRS - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Est. Completion | 1998-10 |
| Phase | Phase 2 |
What the finished NCT00000848 record still lists
NCT00000848 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (68% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00000848 lists 16 locations in 9 states (New York, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT00000848 about?
NCT00000848 is a clinical study titled "The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year". To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA. Resistance to anti-HIV agents occurs with ...
What is the current status of trial NCT00000848?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. Estimated completion is 1998-10.
What conditions does trial NCT00000848 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000848?
The interventions under investigation include: Indinavir sulfate (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00000848?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000848 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000848's enrollment target sits among peer trials
144 218th of 542 higher than 324 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS